Less protease-resistant PrP in a patient with sporadic CJD treated with intraventricular pentosan polysulphate

Acta Neurologica Scandinavica

Volumn 121, Issue 2, 2010, Pages 127-130

  Terada, T ^a   Tsuboi, Y ^b   Obi, T ^a   Doh Ura, K ^c   Murayama, S ^d   Kitamoto, T ^c   Yamada, T ^b   Mizoguchi, K ^a  

^a SHIZUOKA INSTITUTE OF EPILEPSY AND NEUROLOGICAL DISORDERS   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

Creutzfeldt Jakob disease; Intraventricular infusion; Pentosan polysulphate; Prion protein

Indexed keywords

BRAIN PROTEIN; METHIONINE; PENTOSAN POLYSULFATE; PRION PROTEIN; PROTEASE RESISTANT PRION PROTEIN; UNCLASSIFIED DRUG;

AGED; AUTOPSY; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CASE REPORT; CAUSE OF DEATH; CEREBROSPINAL FLUID ANALYSIS; CHEMOLUMINESCENCE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEUROPATHOLOGY; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PNEUMONIA; POLYACRYLAMIDE GEL ELECTROPHORESIS; SUBDURAL EFFUSION; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; WESTERN BLOTTING;

AGED; BRAIN; CREUTZFELDT-JAKOB SYNDROME; FATAL OUTCOME; FEMALE; HUMANS; NEUROPROTECTIVE AGENTS; PENTOSAN SULFURIC POLYESTER; PRIONS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 74349095761     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2009.01272.x     Document Type: Note

References (10)

1. Doh-ura K, Ishikawa K, Murakami-Kubo I et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion of animal models. J Virol 2004 78 : 4999 5006.
2. Parry A, Baker I, Stacey R, Wimalaratna S. Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate. J. Neurol Neurosurg Psychiat 2007 78 : 733 734.
3. Todd NV, Morrow J, Doh-ura K et al. Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. J Infect 2005 50 : 394 396.
4. Whittle IR, Knight RSG, Will RG. Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease. Acta Neurochir (Wien) 2006 148 : 677 679.
5. Rainov NG, Tsuboi Y, Krolak-Salmon P, Vighetto A, Doh-Ura K. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? Expert Opin Biol Ther 2007 7 : 713 726.
6. Bone I, Belton L, Walker AS, Darbyshire J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol 2008 15 : 458 464.
7. Hizume M, Kobayashi A, Teruya K et al. Human Prion Protein (PrP) 219K is converted to PrPSc but shows heterozygous inhibition in variant Creutzfeldt-Jakob disease infection. J Biol Chem 2009 284 : 3603 3609.
8. Farquhar C, Dickinson A, Bruce M. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet 1999 353 : 117.
9. Ladogana A, Casaccia P, Ingrosso L et al. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J Gen Virol 1992 73 : 661 665.
10. Mizusawa H. Prion disease - an overview. Neurol Med 2005 63 : 409 416.